Core Viewpoint - The announcement highlights the upcoming presentation of clinical data for two key drug candidates, CS2009 and CS5001, at the 2025 ESMO annual meeting, marking significant milestones for the company in the oncology sector [1] Group 1: Clinical Trials and Data - The company will present preliminary data from the ongoing Phase I dose-escalation study of CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, involving approximately 70 patients with advanced solid tumors [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, fulfilling ESMO's submission requirements [1] - The clinical data for CS5001, an antibody-drug conjugate targeting ROR1, will also be summarized in the ongoing Phase Ib study design [1]

Core Insights - The upcoming European Society for Medical Oncology (ESMO) annual meeting will take place from October 17 to 21, 2025, in Berlin, Germany [1] - The company has announced that preliminary data for its core clinical pipeline, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), will be presented at the ESMO conference [1] - CS2009's abstract includes data from 9 patients as of the submission deadline on May 8, 2025, fulfilling ESMO's submission requirements [1] - The company will showcase initial data from a Phase I dose-escalation study of CS2009 involving approximately 70 patients with advanced solid tumors, marking the first known clinical data on a PD-1/VEGF/CTLA-4 tri-specific antibody globally [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前 瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任 何前瞻性陳述及預料之外的事件。請細閱本公告，並理解我們的實際未來業績或表現可能與預期有 重大差異。本公告中有關我們或任何董事及╱或本公司的意向的陳述或提述乃於本公告刊發日期作 出。任何該等意向均可能因未來發展而出現變動。 在即將正式召開的ESMO大會上，基石藥業將以壁報形式展示CS2009在約70例晚期實體瘤患者 中的I期劑量遞增臨床研究初步數據，這也將是目前已知全球首個關於PD-1/VEGF/CTLA-4三 特異性抗體的臨床數據發表。 CStonePharmaceuticals 基石藥業 ( 於開曼群島註冊成立的有限公司 ) (股份代號：2616) 自願 公告 ESMO 2025前瞻：基石藥業將公佈PD-1/VEGF/CTLA- ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 基石藥業 | | | | | | 呈交日期: | 2025年10月8日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02616 | 說明 | | | | 本月底法定/註冊股本總額： USD 200,000 第 1 頁 共 10 頁 v 1.1.1 FF301 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 2,000,000,000 USD 0.0001 USD 200,000 增加 / 減少 (-) 0 USD 0 本月底結存 2,000,000,000 USD 0.0001 USD 200,000 FF301 II. 已發行股份及/或 ...

CStone Pharmaceuticals 基石藥業 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) Stock Code 股份代號 : 2616 Interim Report 2025 中期報告 目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 財務摘要 | 4 | | 業務摘要 | 6 | | 管理層討論及分析 | 10 | | 董事及高級管理層 | 25 | | 其他資料 | 34 | | 簡明綜合財務報表審閱報告 | 58 | | 簡明綜合損益及其他全面收益表 | 59 | | 簡明綜合財務狀況表 | 60 | | 簡明綜合權益變動表 | 62 | | 簡明綜合現金流量表 | 63 | | 簡明綜合財務報表附註 | 64 | | 釋義 | 81 | 公司資料 董事會 執行董事 楊建新博士 （首席執行官） 非執行董事 李偉博士 （主席） Kenneth Walton Hitchner III先生 林向紅先生 （於二零二五年六月二十五日退任） 胡正國先生 獨立非執 ...

Core Insights - The latest shareholder equity disclosures for companies including Stone Four Pharmaceutical Group, Cornerstone Pharmaceuticals-B, and Huilyang Technology were made on September 26, 2025 [1] Group 1: Stone Four Pharmaceutical Group (02005) - China Pharmaceutical increased its holdings from 884 million shares to 885 million shares, representing a holding percentage change from 29.95% to 29.99% [2] - Qu Jiguang raised his stake from 1.204 billion shares to 1.205 billion shares, with a holding percentage change from 40.78% to 40.82% [2] Group 2: Cornerstone Pharmaceuticals-B (02616) - Yang Jianxin increased his holdings from 70.0927 million shares to 70.2427 million shares, with a holding percentage change from 4.75% to 4.76% [2] Group 3: Huilyang Technology (01860) - Song Xiaofei reduced his holdings from 2.1924 million shares to 2.0004 million shares, with a holding percentage change from 0.14% to 0.13% [2]

香港联交所最新数据显示，9月25日，Yang Jianxin增持基石药业（02616）15万股，每股作价7.7982港 元，总金额约为116.97万港元。增持后最新持股数目约为7024.27万股，持股比例为4.76%。 来源：新浪港股 ...

Group 1 - Yang Jianxin increased his stake in 基石药业 (02616) by purchasing 150,000 shares at a price of 7.7982 HKD per share, totaling approximately 1.1697 million HKD [1] - After the purchase, the total number of shares held by Yang Jianxin is approximately 70.2427 million, representing a holding percentage of 4.76% [1]

智通财经APP获悉，香港联交所最新数据显示，9月25日，Yang Jianxin增持基石药业(02616)15万股，每 股作价7.7982港元，总金额约为116.97万港元。增持后最新持股数目约为7024.27万股，持股比例为 4.76%。 ...

Core Insights - The company announced the completion of the first patient enrollment in the global multicenter Phase II clinical trial for its core pipeline product CS2009, a tri-specific antibody targeting PD-1/VEGF/CTLA-4 [1] - The trial is actively enrolling patients in Australia and China, with plans to expand to the United States in the future [1] - The Phase II trial employs a multi-cohort parallel expansion design, covering 15 cohorts and various solid tumor indications, focusing on evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) characteristics, and efficacy of CS2009 as a monotherapy and in combination therapy [1]